Navigation Links
Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
Date:2/11/2008

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sigma-Tau SpA have announced an agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system in six European countries: Italy, France, Germany, Netherlands, Belgium and Luxembourg. Under the terms of the agreement, Sigma-Tau will oversee all necessary regulatory filings, and will be responsible for all marketing and sales of Zingo in their territory.

"In Sigma-Tau, we have selected an experienced partner that can quickly and effectively maximize the Zingo opportunity in Europe and we look forward to an excellent collaborative relationship. Sigma-Tau has a proven commercial infrastructure, including a hospital sales force, and a strong network in Europe," said John P. McLaughlin, chief executive officer of Anesiva. "This licensing agreement covers the majority of Europe and we are currently in advanced discussions with other potential partners for certain additional countries."

"Sigma-Tau seeks to help improve health and quality of life for all. Our agreement to bring Zingo to European markets fits perfectly with this aim, and we are eager to make this FDA-approved product available to patients who otherwise might not have access to it for the reduction of pain associated with peripheral venous access procedures," said Ugo Di Francesco, Executive Vice President and Chief Executive Officer at Sigma-Tau.

The agreement between Anesiva and Sigma-Tau includes an upfront payment to Anesiva and transfer price, as well as milestone payments; additional terms were not disclosed.

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral I.V. insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo was approved by the U.S. Food and Drug Administration (FDA) in August 2007 to reduce the pain associated with peripheral I.V. insertions or blood draws in children three to 18 years of age. In clinical trials, the most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema).

About Sigma-Tau Group

Sigma-Tau is a leading research-based Italian pharmaceutical company with a 2007 consolidated turnover equal to approximately US$980 million, and over 2,500 employees worldwide. Therapeutic areas in which the company's research and development are focused include cardiovascular disease, metabolism, oncology, immunology, and central and nervous system disorders, with 47 projects, 30 clinical indications studied with 17 proprietary molecules, most of which are new and original. Sigma-Tau has operating subsidiaries throughout Europe and the United States and maintains a presence in all of the world's major pharmaceutical markets. For additional information about Sigma-Tau, please visit http://www.sigma-tau.it.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
2. Anesiva Announces Upcoming Webcasts and Conference Participation
3. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
4. Anesiva to Present at BIO InvestorForum on October 11, 2007
5. Anesiva to Unveil Zingo(TM) Commercialization Plans
6. URAC Announces Four More Companies in Process to Earn New Pharmacy Quality Management Accreditations
7. MGT Capital Investments, Inc. Announces Subsidiarys Preliminary Agreement to Acquire Maydeal.com
8. Dialysis Corporation of America Announces Opening of New Dialysis Center in Ohio
9. Rural/Metro Announces Results for Fiscal 2008 Second Quarter
10. Brookdale Senior Living Announces Changes in Senior Management and Board of Directors
11. Tubbs Jones Announces Over $36 Million in Construction Projects for Cleveland VA Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: